This article is more than 5 years old. Information may no longer be current.

Alimera Sciences receives $15.9 million to develop Medidur

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ATLANTA — Alimera Sciences Inc. has received $15.9 million of venture capital, the second half of a round of financing that was initiated in November 2005, the company announced.

The additional resources will be used to further develop the company's Medidur implant, which is used to deliver fluocinolone acetonide to the posterior segment. That device is being evaluated in a phase 3 trial for treatment of diabetic macular edema. The company will also use the capital to expand its development pipeline and to "capitalize on strategic opportunities as they arise," company officials said in a press release.